Cellerant
Therapeutics is a biotechnology company that develops immunotherapies for oncology and blood-related disorders... Read moreCellerant
Therapeutics is a biotechnology company that develops immunotherapies for oncology and blood-related disorders... Read more
News
Dec 17, 2020
Business Wire
Press Release: Cellerant : ONK Therapeutics Announces Three Exclusive Option License Agreements, Which Extend and Strengthen its Dual-Targeted NK Cell Therapy Pipeline
Mar 10, 2020
MarketScreener
Cellerant: Cantargia publ : Cantargia acquires Cellerant IP on IL1RAP
Nov 29, 2018
PharmiWeb
Cellerant: Cellerant Therapeutics, Inc. Presents Additional Phase 2 Results Showing Romyelocel-L Reduces Risk of Infections in AML Patients Undergoing High Dose Ara-C-Based (HiDAC) Induction Chemotherapy
Sep 12, 2018
BioPortfolio
Cellerant: Cellerant Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13042018 Prices from USD $250
Jul 23, 2018
BioPortfolio
Cellerant: Cellerant Therapeutics Inc. Publishes Preclinical Data Highlighting Potential of its CLL1Targeting AntibodyDrug Conjugate to Treat Acute Myeloid Leukemia
Jul 02, 2018
BioPortfolio
Cellerant: Cellerant Therapeutics Inc. Announces FDA Grants Regenerative Medicine Advanced Therapy RMAT Designation for RomyelocelL to Prevent Infections During Neutropenia
Jun 18, 2018
FinanzNachrichten
Cellerant: Cellerant Therapeutics, Inc. Presents Phase 2 Results Showing CLT-008 Significantly Reduces Risk of Infections in AML Patients Undergoing Standard Induction Chemotherapy
May 17, 2018
FinanzNachrichten
Cellerant: Cellerant Therapeutics, Inc. to Present Results of Phase 2 Clinical Trial of CLT-008 at American Society of Clinical Oncology (ASCO) 2018 Annual Meeting and European Hematology Association (EHA) 23rd Congress
Mar 09, 2018
BioPortfolio
Cellerant: Cellerant Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 27022018 Prices from USD $250
Aug 22, 2017
BioSpace
Cellerant: Cellerant Therapeutics, Inc. Awarded $6.86 Million Grant From To Support Development Of Novel Antibody-Drug Conjugate For AML
Cellerant Competitors
1
2
3
4
5
6
7
8
9
10